BioMaxima SA
WSE:BMX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (32.4), the stock would be worth zł-7.68 (165% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -49.5 | zł11.74 |
0%
|
| Industry Average | 32.4 | zł-7.68 |
-165%
|
| Country Average | 18.5 | zł-4.37 |
-137%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
B
|
BioMaxima SA
WSE:BMX
|
49.2m PLN | -49.5 | 75.9 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 48.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 26.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 18 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 26 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | -25.4 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.6 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 33.7 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 10.3 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -115.1 | -36.5 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 7.5 |
| Median | 18.5 |
| 70th Percentile | 27.4 |
| Max | 2 825.7 |
Other Multiples
BioMaxima SA
Glance View
Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.
